Genitourinary (GU) Cancer
Roche is leading the investigation of new options for patients suffering from genitourinary cancer, exploring the potential of cancer immunotherapy and treatment tailored to individuals.
ASCO GU 2020
IMvigor130 Clinical Trial in Patients With Metastatic Urothelial Carcinoma: Analysis of Upper Tract and Lower Tract Subgroups
This analysis from IMvigor130, a randomized phase III study of ▼atezolizumab with or without chemo in patients with previously untreated mUC, investigated the influence of primary tumor site on clinical outcomes. Efficacy and safety in subgroups with lower or upper tract UC are reported.
Phase Ib/II umbrella trial to evaluate the safety and efficacy of multiple 2L cancer immunotherapy (CIT) combinations in advanced/metastatic urothelial carcinoma (mUC): MORPHEUS-mUC
The MORPHEUS platform is comprised of multiple global, open-label, randomized Phase Ib/II trials designed to capture early efficacy signals and evaluate the safety of treatment combinations in patients with different cancers. The MORPHEUS-mUC study is evaluating multiple ▼atezolizumab combination regimens compared with ▼atezolizumab monotherapy in patients with previously platinum treated mUC.
▼Atezolizumab (atezo) therapy for upper tract (UT) urothelial carcinoma (UC): Subgroup analysis of the single-arm international SAUL study in pretreated locally advanced/metastatic urinary tract carcinoma
This post-hoc analysis from SAUL, a single-arm phase IIIb study of single-agent ▼atezolizumab in patients with mUC, investigated clinical outcomes according to the primary tumor site. Efficacy and safety are reported in bladder or upper tract disease subgroups.
IMvigor130: a phase III study of atezolizumab with or without platinum-based chemotherapy in previously untreated metastatic urothelial carcinoma
This presentation reports the primary efficacy and safety data for the Phase 3 IMvigor130 trial investigating ▼atezolizumab with or without chemotherapy versus placebo with chemotherapy in patients with metastatic urothelial cancer who have not been previously treated. With a median follow-up of 11.8 months, final PFS, interim OS, ORR, DOR, and safety results will be shown.
Dr. Grande discusses IMvigor130: a phase III study of atezolizumab with or without platinum-based chemotherapy in previously untreated metastatic urothelial carcinoma
In this video, Dr. Grande discusses the Phase 3 IMvigor130 trial investigating atezolizumab with or without chemotherapy versus placebo with chemotherapy in patients with metastatic urothelial cancer who have not been previously treated. He reviews the study design, final PFS, interim OS, ORR, DOR, safety results, as well as the study results in comparison to the current treatment landscape.
Safety and efficacy of ▼atezolizumab in patients with autoimmune disease: subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma
In prespecified analyses of the subgroup of 35 patients with pre-existing autoimmune disease (AID) treated with ▼atezolizumab for urinary tract carcinoma in the single-arm Phase IIIb SAUL study, incidences of adverse events (AEs) of special interest and treatment-related AEs appeared acceptable. Efficacy in patients with AID seemed at least similar to efficacy in non-AID patients. Treating patients with AID requires caution but AID is not a barrier to ▼atezolizumab therapy per se.
Bladder Cancer: The Facts
Bladder cancer is one of several cancers associated with a high rate of mutations, which may be linked to a heightened immunogenicity. Learn more about the role of tumour-infiltrating immune cells and the pathways governing the immune response.